Cost-effectiveness of biological agents used in ulcerative colitis

Jeannie K Lee, Derek H. Tang, Lea Mollon, Edward P Armstrong

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Ulcerative colitis (UC) produces bloody diarrhoea, severe abdominal pain, and need for clinic visits, hospitalizations, and surgeries. UC results in reduced health-related quality of life for patients and large direct medical and indirect costs for health systems and employers. Patients with the most severe disease require the most medical services, and these patients have larger costs than patients with mild or moderate disease. Despite biological therapies being quite expensive, they are indicated for patients unresponsive to initial standard therapies. Future hospitalizations may be reduced by starting a biological treatment. Cost-effectiveness results vary between countries, health systems, and model designs. Since restorative proctocolectomy can be curative, this surgery dominates biological therapy by being both less costly and more effective when measuring health system costs and patient qualityadjusted life years for 20 years. However the dose, duration, and effectiveness of biological treatments significantly impact estimates of their cost-effectiveness.

Original languageEnglish (US)
Pages (from-to)949-960
Number of pages12
JournalBest Practice and Research: Clinical Gastroenterology
Volume27
Issue number6
DOIs
StatePublished - Dec 2013

Fingerprint

Biological Factors
Ulcerative Colitis
Cost-Benefit Analysis
Biological Therapy
Employer Health Costs
Hospitalization
Restorative Proctocolectomy
Pain Clinics
Ambulatory Care
Health Care Costs
Abdominal Pain
Diarrhea
Quality of Life
Costs and Cost Analysis
Health
Therapeutics

Keywords

  • Biologics
  • Cost
  • Cost-effectiveness
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Cost-effectiveness of biological agents used in ulcerative colitis. / Lee, Jeannie K; Tang, Derek H.; Mollon, Lea; Armstrong, Edward P.

In: Best Practice and Research: Clinical Gastroenterology, Vol. 27, No. 6, 12.2013, p. 949-960.

Research output: Contribution to journalArticle

@article{38e8c054b5844aa08dae1354047ba789,
title = "Cost-effectiveness of biological agents used in ulcerative colitis",
abstract = "Ulcerative colitis (UC) produces bloody diarrhoea, severe abdominal pain, and need for clinic visits, hospitalizations, and surgeries. UC results in reduced health-related quality of life for patients and large direct medical and indirect costs for health systems and employers. Patients with the most severe disease require the most medical services, and these patients have larger costs than patients with mild or moderate disease. Despite biological therapies being quite expensive, they are indicated for patients unresponsive to initial standard therapies. Future hospitalizations may be reduced by starting a biological treatment. Cost-effectiveness results vary between countries, health systems, and model designs. Since restorative proctocolectomy can be curative, this surgery dominates biological therapy by being both less costly and more effective when measuring health system costs and patient qualityadjusted life years for 20 years. However the dose, duration, and effectiveness of biological treatments significantly impact estimates of their cost-effectiveness.",
keywords = "Biologics, Cost, Cost-effectiveness, Ulcerative colitis",
author = "Lee, {Jeannie K} and Tang, {Derek H.} and Lea Mollon and Armstrong, {Edward P}",
year = "2013",
month = "12",
doi = "10.1016/j.bpg.2013.09.007",
language = "English (US)",
volume = "27",
pages = "949--960",
journal = "Bailliere's Best Practice and Research in Clinical Gastroenterology",
issn = "1521-6918",
publisher = "Bailliere Tindall Ltd",
number = "6",

}

TY - JOUR

T1 - Cost-effectiveness of biological agents used in ulcerative colitis

AU - Lee, Jeannie K

AU - Tang, Derek H.

AU - Mollon, Lea

AU - Armstrong, Edward P

PY - 2013/12

Y1 - 2013/12

N2 - Ulcerative colitis (UC) produces bloody diarrhoea, severe abdominal pain, and need for clinic visits, hospitalizations, and surgeries. UC results in reduced health-related quality of life for patients and large direct medical and indirect costs for health systems and employers. Patients with the most severe disease require the most medical services, and these patients have larger costs than patients with mild or moderate disease. Despite biological therapies being quite expensive, they are indicated for patients unresponsive to initial standard therapies. Future hospitalizations may be reduced by starting a biological treatment. Cost-effectiveness results vary between countries, health systems, and model designs. Since restorative proctocolectomy can be curative, this surgery dominates biological therapy by being both less costly and more effective when measuring health system costs and patient qualityadjusted life years for 20 years. However the dose, duration, and effectiveness of biological treatments significantly impact estimates of their cost-effectiveness.

AB - Ulcerative colitis (UC) produces bloody diarrhoea, severe abdominal pain, and need for clinic visits, hospitalizations, and surgeries. UC results in reduced health-related quality of life for patients and large direct medical and indirect costs for health systems and employers. Patients with the most severe disease require the most medical services, and these patients have larger costs than patients with mild or moderate disease. Despite biological therapies being quite expensive, they are indicated for patients unresponsive to initial standard therapies. Future hospitalizations may be reduced by starting a biological treatment. Cost-effectiveness results vary between countries, health systems, and model designs. Since restorative proctocolectomy can be curative, this surgery dominates biological therapy by being both less costly and more effective when measuring health system costs and patient qualityadjusted life years for 20 years. However the dose, duration, and effectiveness of biological treatments significantly impact estimates of their cost-effectiveness.

KW - Biologics

KW - Cost

KW - Cost-effectiveness

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84887181615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887181615&partnerID=8YFLogxK

U2 - 10.1016/j.bpg.2013.09.007

DO - 10.1016/j.bpg.2013.09.007

M3 - Article

C2 - 24182613

AN - SCOPUS:84887181615

VL - 27

SP - 949

EP - 960

JO - Bailliere's Best Practice and Research in Clinical Gastroenterology

JF - Bailliere's Best Practice and Research in Clinical Gastroenterology

SN - 1521-6918

IS - 6

ER -